Skip to Content

New Improvement of PFS in First-Line Treatment of Advanced Renal-Cell Carcinoma

Data from ASCO GU23 show better improvement of progression-free survival (PFS) for advanced renal-cell carcinoma (aRRC) patients receiving cabozantinib together with nivolumab and ipilimumab, when compared to adding placebo. However, subgroup analysis suggests better outcomes for patients in intermediate IMDC risk group.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top